What Is The Comparative Market Size Outlook For The Metered Dose Inhaler Devices Market Over The 2026–2030Timeframe?
The metered dose inhaler devices market size has grown strongly in recent years. It will grow from $16.23 billion in 2025 to $17.12 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to rising asthma prevalence, increasing COPD incidence, widespread use of inhalation therapy, physician preference for mdIs, availability of generic inhalers.
The metered dose inhaler devices market size is expected to see strong growth in the next few years. It will grow to $21.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to growth of smart inhalers, environmental regulations on propellants, homecare treatment expansion, digital adherence monitoring demand, emerging respiratory therapies. Major trends in the forecast period include smart dose tracking inhalers, breath-actuated inhalation technology, compact and portable device designs, dose accuracy enhancement, eco-friendly propellant adoption.
Claim Your Free Report Sample Today:
What Significant Demand Drivers Are Anticipated To Influence The Metered Dose Inhaler Devices Market Over The Coming Years?
The increasing prevalence of chronic obstructive pulmonary diseases is expected to propel the growth of the metered dose inhaler devices market going forward. Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by airflow obstruction, typically caused by long-term exposure to irritants such as cigarette smoke, leading to symptoms such as shortness of breath, coughing, and wheezing. The increasing prevalence of chronic obstructive pulmonary disease (COPD) is driven by factors such as tobacco use, air pollution, aging populations, and delayed diagnosis or treatment. Metered dose inhaler (MDI) devices help manage chronic obstructive pulmonary disease (COPD) by delivering medication directly to the lungs, providing fast relief and improving airflow. For instance, in December 2023, according to the National Institutes of Health, a US-based government agency, the number of COPD cases is projected to rise from 532 million in 2030 to a total of 592 million by 2050. Therefore, the increasing prevalence of chronic obstructive pulmonary diseases is driving the growth of the metered dose inhaler devices market.
What Segment Divisions Provide The Most Valuable Insights Into The Metered Dose Inhaler Devices Market?
The metered dose inhaler devices market covered in this report is segmented –
1) By Type: Desktop Metered Dose Inhaler Devices, Portable Metered Dose Inhaler Devices, Other Types
2) By Distribution Channel: Online, Offline
3) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Other Applications
4) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Desktop Metered Dose Inhaler Devices: Standard desktop MDI devices, High-performance desktop MDI devices, Smart desktop MDI devices
2) By Portable Metered Dose Inhaler Devices: Conventional portable MDI devices, Advanced portable MDI devices, Smart portable MDI devices
3) By Other Types: Nebulizer-Based MDI devices, Dry powder inhaler (DPI) combined devices, Soft mist inhaler (SMI) devices, Other specialized MDI devices
What Key Market Trends Are Contributing To The Ongoing Development Of The Metered Dose Inhaler Devices Market?
Major companies operating in the metered dose inhaler devices market are focused on developing technologically advanced solutions, such as pressurized metered dose inhalers, to enhance drug delivery efficiency and improve patient compliance. Pressurized metered-dose inhalers (pMDIs) are inhalation devices that deliver a precise amount of medication in aerosol form using a pressurized propellant. For instance, in July 2023, Lupin Limited, an India-based pharmaceutical company, launched Luforbec 100/6, a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany. This product combines beclometasone (100 µg) and formoterol (6 µg), providing an effective solution for patients requiring combination therapy. Notably, Luforbec is priced approximately 47% lower than the fixed reference price, enhancing its accessibility. With asthma affecting about 5% of adults in Germany, this launch underscores Lupin's commitment to addressing critical healthcare needs and improving patient outcomes in respiratory care.
Who Are The Key Companies Actively Operating Within The Metered Dose Inhaler Devices Market?
Major companies operating in the metered dose inhaler devices market are Pfizer Inc., Merck & Co. Inc., AstraZeneca PLC, GlaxoSmithKline plc, 3M Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Berry Global Inc., AptarGroup Inc., Philips Healthcare, Chiesi Farmaceutici S.p.A., Cipla Limited, Gerresheimer AG, Zydus Lifesciences Limited, Mylan N.V., Nemera, Beximco Pharmaceuticals Limited, Cohero Health Inc., Bespak Europe Ltd., Trudell Medical International, Iconovo AB
Get Your In-Depth Metered Dose Inhaler Devices Market Report Now:
Which Regions Are Generating The Highest Demand Within The Metered Dose Inhaler Devices Market?
North America was the largest region in the metered dose inhaler devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metered dose inhaler devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment